Patents Assigned to Mylan Pharmaceuticals, Inc.
-
Patent number: 10844103Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.Type: GrantFiled: October 10, 2017Date of Patent: November 24, 2020Assignee: Mylan Pharmaceuticals Inc.Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
-
Patent number: 9730890Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: GrantFiled: December 27, 2013Date of Patent: August 15, 2017Assignee: Mylan Pharmaceuticals, Inc.Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
-
Patent number: 9205062Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.Type: GrantFiled: November 17, 2008Date of Patent: December 8, 2015Assignee: Mylan Pharmaceuticals, Inc.Inventors: Kristin Jackson, Kenneth J. Miller, II
-
Patent number: 9198877Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.Type: GrantFiled: November 17, 2009Date of Patent: December 1, 2015Assignee: Mylan Pharmaceuticals, Inc.Inventors: Kristin Jackson, Kenneth J. Miller
-
Patent number: 8962036Abstract: Disintegrable preparations of lanthanum carbonate prepared by co-precipitation, facilitating the manufacture of oral pharmaceutical dosage forms such as tablets, capsules, powders, granules, and sprinkles, and the use of such dosage forms to treat subjects with hyperphosphatemia are disclosed.Type: GrantFiled: January 21, 2010Date of Patent: February 24, 2015Assignee: Mylan Pharmaceuticals Inc.Inventors: Andrea Blum Works, John Twist, Okey Noe
-
Patent number: 8945615Abstract: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, an extended release polymer, and an acid. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration.Type: GrantFiled: February 17, 2009Date of Patent: February 3, 2015Assignee: Mylan Pharmaceuticals Inc.Inventors: Mummini Aruna Murty, Boyong Li
-
Patent number: 8945616Abstract: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, and an extended release polymer. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration.Type: GrantFiled: February 17, 2009Date of Patent: February 3, 2015Assignee: Mylan Pharmaceuticals Inc.Inventors: Mummini Aruna Murty, Boyong Li
-
Patent number: 8912174Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.Type: GrantFiled: September 4, 2003Date of Patent: December 16, 2014Assignee: Mylan Pharmaceuticals Inc.Inventor: Imtiaz Chaudry
-
Publication number: 20130319595Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.Type: ApplicationFiled: April 29, 2013Publication date: December 5, 2013Applicant: Mylan Pharmaceuticals, Inc.Inventors: Kenneth J. Miller, Sharad K. Govil, Kuljit Singh Bhatia
-
Patent number: 8486452Abstract: A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate release and controlled release dosage forms.Type: GrantFiled: July 20, 2007Date of Patent: July 16, 2013Assignee: Mylan Pharmaceuticals Inc.Inventors: David T. Rossi, Boyong Li, James Paul McCall
-
Patent number: 8449907Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.Type: GrantFiled: July 27, 2011Date of Patent: May 28, 2013Assignee: Mylan Pharmaceuticals, Inc.Inventors: Kenneth J. Miller, II, Sharad K. Govil, Kuljit Singh Bhatia
-
Publication number: 20120145320Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.Type: ApplicationFiled: July 27, 2011Publication date: June 14, 2012Applicant: MYLAN PHARMACEUTICALS, INC.Inventors: Kenneth J. Miller, Sharad K. Govil, Kulijit Singh Bhatia
-
Patent number: 8114912Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: GrantFiled: May 24, 2010Date of Patent: February 14, 2012Assignee: Mylan Pharmaceuticals, Inc.Inventors: Imtiaz A. Chaudry, Stephen Pham, Partha S. Banerjee
-
Patent number: 8110226Abstract: A drug composition comprising a coated bead is used in the manufacture of immediate release and/or controlled release drug compositions. In a specific embodiment, the bead includes an inert core of a water-soluble or water-swellable material, which has been coated with a seal layer formed from a non-polymeric hydrophobic material. The immediate and/or controlled release beads may be used to form tablets or capsules. A method of making the beads by sequential deposition of multiple layers on the inert cores is also described.Type: GrantFiled: July 20, 2007Date of Patent: February 7, 2012Assignee: Mylan Pharmaceuticals Inc.Inventor: Boyong Li
-
Publication number: 20090238861Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.Type: ApplicationFiled: June 2, 2009Publication date: September 24, 2009Applicant: Mylan Pharmaceuticals, Inc.Inventors: Kenneth J. Miller, II, Sharad K. Govil, Kuljit Singh Bhatia
-
Publication number: 20090238873Abstract: Extended release pharmaceutical formulations are disclosed wherein the formulations contain an extended release portion and an immediate release portion, the extended release portion comprising an active pharmaceutical ingredient and a wax. Methods of making such extended release pharmaceutical formulations are also disclosed.Type: ApplicationFiled: March 18, 2009Publication date: September 24, 2009Applicant: Mylan Pharmaceuticals, Inc.Inventors: Sarat C. Chattaraj, Pavan Bhat, Glenn A. Redelman, David J. Wargo, William Addicks
-
Patent number: 7556823Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended in one or more solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.Type: GrantFiled: October 28, 2008Date of Patent: July 7, 2009Assignee: Mylan Pharmaceuticals, Inc.Inventors: Kenneth J. Miller, II, Sharad K. Govil, Kuljit Singh Bhatia
-
Publication number: 20090022807Abstract: A drug composition comprising a coated bead is used in the manufacture of immediate release and/or controlled release drug compositions. In a specific embodiment, the bead includes an inert core of a water-soluble or water-swellable material, which has been coated with a seal layer formed from a non-polymeric hydrophobic material. The immediate and/or controlled release beads may be used to form tablets or capsules. A method of making the beads by sequential deposition of multiple layers on the inert cores is also described.Type: ApplicationFiled: July 20, 2007Publication date: January 22, 2009Applicant: MYLAN PHARMACEUTICALS INCInventor: Boyong Li
-
Publication number: 20090022797Abstract: A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate release and controlled release dosage forms.Type: ApplicationFiled: July 20, 2007Publication date: January 22, 2009Applicant: MYLAN PHARMACEUTICALS INCInventors: David T. Rossi, Boyong Li, James Paul McCall
-
Publication number: 20070259027Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.Type: ApplicationFiled: May 2, 2007Publication date: November 8, 2007Applicant: MYLAN PHARMACEUTICALS INC.Inventors: Kenneth Miller, Sharad Govil, Kuljit Bhatia